GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.
Company Details
- Employees
- 46
- Address
- 3160 Porter Dr, Palo Alto,california 94304,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://gondolabio.com/
- Keywords
- with academic innovation..
- HQ
- Palo Alto, California
Gondolabio Questions
Gondolabio's website is https://gondolabio.com/
Gondolabio's LinkedIn profile is https://www.linkedin.com/company/gondolabio
Gondolabio has
46 employees.
View email and phone details for 46
employees at Gondolabio.
Gondolabio's industry is
Biotechnology Research
Gondolabio's top competitors are
Birdwood Therapeutics,
Portal Therapeutics,
Marea Therapeutics,
Bbot,
Sonoma Biotherapeutics, Inc.,
Oxford Biotherapeutics,
Bridgebio,
Mirador Therapeutics,
Engage Bio,
Gate Bioscience.
Gondolabio's categories are Biotechnology Research
